Disc Medicine

MIRROR is a phase 1 dose-finding study sponsored by Disc Medicine investigating multispectral and bimodal fluorescent-guided surgery (FGS) for high-grade glioma margin assessment. The trial combines cetuximab-IRDye800CW, a near-infrared fluorescent imaging agent conjugated to the approved EGFR-targeting monoclonal antibody cetuximab (ERBITUX), with 5-aminolevulinic acid (5-ALA), a protoporphyrin IX precursor used in neurosurgical visualization. The study aims to refine intraoperative margin delineation in glioblastoma patients, addressing a critical unmet need in surgical oncology where incomplete resection correlates with poor prognosis. Cetuximab is globally approved for multiple cancer indications; the IRDye800CW conjugate represents a novel application combining established pharmacology with advanced optical imaging. The trial is currently active with NCT identifier 2024-513392-40-01. No regulatory approvals, expected milestones, or peak sales projections have been disclosed. The program represents an investigational approach to intraoperative guidance rather than a systemic therapeutic, positioning it within the emerging surgical imaging space.

Glioblastoma remains one of oncology's most challenging malignancies, with median overall survival approximately 15 months despite multimodal therapy. Gross total resection (GTR) is a primary prognostic factor, yet achieving complete tumor removal while preserving eloquent brain tissue remains technically difficult with standard white-light visualization alone. Current intraoperative guidance relies on 5-ALA fluorescence (approved in Europe and under investigation in the US) or neuronavigation, both with limitations in real-time margin definition. The MIRROR trial explores bimodal imaging—combining EGFR-targeted near-infrared fluorescence (cetuximab-IRDye800CW) with 5-ALA—to potentially enhance tumor margin visualization and surgical precision. This addresses a substantial unmet need: improved intraoperative decision-making could increase GTR rates and potentially improve survival outcomes. The competitive landscape includes 5-ALA monotherapy and emerging optical imaging technologies; however, few therapies specifically target the surgical guidance niche for glioblastoma. Commercial significance is moderate but focused: success could establish a new standard-of-care adjunct in neurosurgical oncology, with applications potentially extending to other CNS and non-CNS tumors. The patient population—glioblastoma patients undergoing resection—is substantial but specialized, limiting peak market size compared to systemic therapies.

Drug Class: Monoclonal antibody conjugate (optical imaging agent); investigational modality for intraoperative surgical guidance.

Mechanism of Action: Cetuximab-IRDye800CW combines cetuximab, an EGFR-targeting chimeric monoclonal antibody, with IRDye800CW, a near-infrared fluorophore. The conjugate binds EGFR-expressing tumor cells, enabling real-time near-infrared fluorescence visualization during surgery. When combined with 5-ALA (which generates protoporphyrin IX fluorescence in the red spectrum), bimodal imaging provides complementary visualization of tumor margins.

Route of Administration: Intravenous (cetuximab component); 5-ALA is typically administered orally.

Target: EGFR (epidermal growth factor receptor).

Related Therapies: Cetuximab (ERBITUX) is approved globally for metastatic colorectal cancer, head and neck squamous cell carcinoma, and other malignancies. 5-ALA (Gliolan) is approved in Europe for glioblastoma surgery and under investigation in the US. Other intraoperative imaging agents include fluorescein and indocyanine green; however, EGFR-targeted near-infrared agents represent a newer class.

First Approval: Cetuximab was first approved by the FDA in 2004 (BLA125084); the IRDye800CW conjugate is investigational and not yet approved.

Patent Status: Not disclosed in available facts.

FDA (United States): Cetuximab (ERBITUX, BLA125084) is approved for multiple indications. Cetuximab-IRDye800CW is investigational; no FDA approval has been disclosed. The MIRROR trial (NCT 2024-513392-40-01) is active under IND authority.

EMA (European Union): Cetuximab is approved (EMEA/H/C/000558, MAH Merck Europe B.V., authorisation date 28/01/2026 per facts). Cetuximab-IRDye800CW regulatory status in Europe is not yet disclosed.

TGA (Australia): Cetuximab (ERBITUX) is approved with multiple PBS codes (10262D, 10265G, 12816M, 12817N, 12820R, 12821T, 4312Y, 4435K, 4436L, 4731B); sponsor Merck Healthcare Pty Ltd, first listed 2011-12-01 with updates 2015-06-01 and 2022-01-01.

NMPA (China): Cetuximab is under clinical investigation in China (NCT03126708, NCT03881787, NCT05497336 listed); cetuximab-IRDye800CW regulatory status not yet disclosed.

PMDA (Japan): Not yet disclosed.

Expected Loss of Exclusivity (LOE) for Cetuximab: Not disclosed in facts.

The IRDye800CW conjugate is investigational globally; regulatory pathway and timelines are not yet disclosed.

Strategic Positioning: MIRROR represents Disc Medicine's entry into the surgical oncology imaging space, a niche but clinically important area. The combination of an approved EGFR-targeting antibody (cetuximab) with a novel near-infrared fluorophore (IRDye800CW) and an established surgical imaging agent (5-ALA) is rationally designed to enhance intraoperative visualization. Success in phase 1 would validate the bimodal imaging approach and potentially support advancement to phase 2 efficacy studies comparing margin assessment and GTR rates versus 5-ALA alone or standard of care.

Competitive Implications: If cetuximab-IRDye800CW demonstrates superior margin visualization compared to 5-ALA monotherapy, it could establish a new standard adjunct in glioblastoma surgery, particularly in EGFR-expressing tumors. However, the market is limited to the surgical setting and glioblastoma population, constraining peak sales potential. No direct systemic therapy competitors are threatened; rather, MIRROR complements existing glioblastoma treatments by improving surgical outcomes.

Future Catalysts: Phase 1 safety and dose-finding data (expected timeline not disclosed); potential phase 2 efficacy trial comparing bimodal versus 5-ALA imaging; regulatory interactions with FDA/EMA regarding imaging agent classification and approval pathway; clinical adoption studies in neurosurgical centers.

Expected Milestones: Phase 1 completion and data presentation; IND/clinical trial authorization for phase 2 (if warranted); potential regulatory guidance meetings with FDA or EMA on imaging agent approval strategy.